CAR-NK-CD19 Cell Therapy (Wuhan Union Hospital)

N/A

Report date: 2024/11/24 20:00:04

Base Information

Drug NameCAR-NK-CD19 Cell Therapy (Wuhan Union Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesWuhan Union Hospital
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWuhan Union Hospital
Active IndicationsN/A
Inactive IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A